Unfractionated heparin is frequently used in tertiary pediatric centers for the prophylaxis and
treatment of thromboembolic disease. Recent evidence suggests that the clinical outcomes …

The incidence of thromboembolic events (TEs) in childhood is greatly underestimated. Two
age groups account for $70% of TEs in childhood: infants and teenagers. There are several …

Low molecular weight heparins potentially have significant advantages over unfractionated
heparin and oral anticoagulants for both the prevention and treatment of thromboembolic …

Background: Unfractionated heparin (UFH) is a widely used anticoagulant. Current
American College of Chest Physicians guidelines for infants extrapolated from adults …

INTRODUCTION: Unfractionated Heparin (UFH) is used widely in paediatrics. Paediatric
specific recommendations for UFH therapy are few, with the majority of recommendations …

Controversies exist over the currently recommended guidelines for the use of low-molecular-
weight heparin (LMWH) in neonates. We retrospectively studied 30 neonates treated with …

Within the last two decades low molecular weight heparins (LMWH) have gained increasing
widespread use as anticoagulants in children. The use of LMWH has been implemented into …

Paediatric recommendations for unfractionated heparin (UFH) management are
extrapolated from adult trials, a practice that may contribute to the inferior UFH‐related …

Low molecular weight heparins (LMWHs) are commonly used in paediatric tertiary
institutions for primary prophylaxis and treatment of thromboembolic events. Despite this …

OBJECTIVE: To compare low-molecular-weight preparations of heparin (LMWH) with
standard heparin in children requiring anticoagulant treatment for thromboembolic disease …